NSPR — InspireMD, Inc.

InspireMD (NSPR) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $3.1 million, up 62% from $1.9 million in Q4 2024.
• U.S. Revenue: $866,000, representing a 74% sequential growth from Q3 2025.
• International Revenue: $2.3 million, a 17% increase year-over-year.
• Gross Profit: $1.2 million (37.5% of revenue), compared to $469,000 (24.1%) in Q4 2024, driven by higher U.S. sales margins (~70%).
• Operating Expenses: $13.3 million, up from $9.8 million, mainly due to increased staffing and marketing for U.S. launch.
• Net Loss: $11.8 million ($0.14 per share), compared to a loss of $9.2 million ($0.19 per share) in Q4 2024.
• Cash Position: $54.2 million in cash and marketable securities, up from $34.6 million at the end of 2024.

2. Strategic Updates and Business Highlights

• CGuard Prime Launch: The company is focused on establishing market leadership in stroke prevention with its CGuard Prime carotid stent, having completed over 500 cases and gained approvals in major U.S. integrated delivery networks (IDNs).
• Operational Expansion: InspireMD is establishing U.S.-based production and increasing manufacturing capacity to meet growing demand.
• Clinical Pipeline: Ongoing trials, including C-GUARDIANS II for TCAR procedures, with expected FDA approval in Q3 2026, and CGUARDIANS III for a fully integrated TCAR solution anticipated to begin enrollment in Q2 2026.
• Sales Force Growth: The U.S. commercial team has expanded to over 30 members, focusing on building coverage and procedural support.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $13 million and $15 million, reflecting a growth of 45% to 65% over 2025.
• Growth Drivers: Anticipated acceleration in U.S. sales in the second half of 2026 due to FDA label expansion for TCAR procedures and the introduction of an enhanced delivery system for CGuard Prime.

4. Bad News, Challenges, or Points of Concern

• Net Loss: The company continues to experience significant net losses, which may raise concerns about sustainability and profitability.
• High Operating Expenses: The increase in operating expenses could pressure margins if revenue growth does not keep pace.
• Controlled Launch: The ongoing controlled launch strategy may limit immediate revenue potential and market penetration, with a gradual rollout to ensure quality and physician comfort with the product.

5. Notable Q&A Insights

• Account Adoption: Approximately 80 centers have conducted cases with CGuard, with over 200 additional centers in the pipeline. The company is focused on converting these into active customers.
• Physician Feedback: Surgeons have expressed enthusiasm for the CGuard Prime platform, viewing it as a potential first-line treatment option, indicating a shift in the market towards a stent-first approach.
• Sales Force Productivity: The company aims for reps to be actively involved in cases nearly every working day, with expectations of increasing productivity as physicians become more comfortable with the product.
• Next-Gen Delivery System: Improvements to the delivery system are expected to be submitted for FDA review, with a relatively quick 30-day review process anticipated.

Overall, InspireMD is positioned for growth with its innovative CGuard Prime product, although it faces challenges related to profitability and the pace of market adoption.